Midwest City, Oklahoma Clinical Trials

A listing of Midwest City, Oklahoma clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 43 clinical trials
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

IMC-F106C is an immune-mobilizing T cell receptor against cancer (ImmTAC ) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a first-in-human trial designed to evaluate the safety and efficacy of IMC-F106C in adult patients who have the appropriate HLA-A2 tissue marker and whose cancer …

University of Oklahoma Peggy and Charles Stephenson Cancer Center
 (6.3 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +9 other locations
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer

A study to assess the efficacy and safety of durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial cancer.

carcinoma
measurable disease
olaparib
endometrial cancer
endometrial carcinoma
Research Site
 (6.3 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +94 other locations
A Study of SY 5609 a Selective CDK7 Inhibitor in Advanced Solid Tumors

This is a dose escalation study and will be the first to administer SY-5609 alone to humans with select advanced solid tumors and in combination with Fulvestrant to patients with HR positive, HER2-negative breast cancer.

screening procedures
solid tumor
measurable disease
alopecia
metastatic breast cancer
Stephenson Cancer Center
 (6.3 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +4 other locations
Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body

This phase III trial studies how well the addition of radiotherapy to the usual treatment (chemotherapy) works compared to the usual treatment alone in treating patients with esophageal and gastric cancer that has spread to a limited number of other places in the body (oligometastatic disease). Radiotherapy uses high energy …

gastric adenocarcinoma
celiac disease
lymphadenopathy
gastric cancer
capecitabine
University of Oklahoma Health Sciences Center
 (6.3 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +254 other locations
Does Insulin Sensitivity Impact the Potential of Metformin to Slow Aging

Aging is the number one risk factor for the majority of chronic diseases. There are no pharmaceutical treatments to slow aging and prolong healthspan. The anti-diabetic drug metformin is considered a likely pharmaceutical candidate to slow aging. In this study, the investigators hypothesize that metformin treatment in subjects free of …

insulin resistance
niddm
diabetes
insulin
insulin sensitivity
University of Oklahoma Health Sciences Center, Oklahoma Shared Clinical and Translational Resources
 (6.3 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +1 other locations
A First-in-human Study Using BDC-1001 in Advanced and HER2-Expressing Solid Tumors

A first-in-human study using BDC-1001 in HER2 expressing advanced malignancies

solid tumor
measurable disease
metastasis
HER2
solid tumour
Bolt Investigative Site
 (6.3 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +6 other locations
Tipifarnib for the Treatment of Advanced Solid Tumors Lymphoma or Histiocytic Disorders With HRAS Gene Alterations a Pediatric MATCH Treatment Trial

This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have spread to other places in the body (advanced), lymphoma, or histiocytic disorders that have HRAS genetic alterations. Tipifarnib may block the growth of cancer cells that have specific genetic changes in …

nervous system disorders
genetic alteration
radiopharmaceutical therapy
graft versus host disease
131i-mibg
University of Oklahoma Health Sciences Center
 (6.3 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +82 other locations
Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma

This is a phase II open-label study investigating the efficacy, safety and pharmacokinetic(PK) properties of OKN-007 combined with temozolomide(TMZ) in patients with recurrent glioblastoma(GBM). All patients will have been previously treated with the standard-of-care treatment which includes surgical resection, radiation and chemotherapy, and in some cases treatment for recurrent disease. …

The University of Oklahoma
 (6.3 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +2 other locations
Assessment of N-95 Facemask for Use in COVID-19 Pandemic in Case of Shortage of Personal Protective Equipment

The purpose of this study is to assess the safety and efficiency of an assembled modified mask in protecting health care workers against Coronavirus in case of any personal protective equipment shortage. At least 20 healthy participants will be recruited to try the modified mask. The modified masks will be …

covid-19
coronavirus infection
Oklahoma City VA Health Care System
 (6.3 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location
Functional Intermuscular Reduction of Spasticity

Investigators will use muscular dry needling in the calf of one lower extremity, followed by treadmill training with functional electrical stimulation.

spasticity
dry needling
electrical stimulation
Oklahoma Medical Research Foundation
 (6.3 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location